About Us

About Us

Cergentis is a privately held genomics company that developed the patented Targeted Locus Amplification (TLA) technology. TLA is a widely published Next Generation Sequencing (NGS) technology that offers unique advantages in the implementation of precision medicine and advanced genetic engineering.

Cergentis has established itself as the go-to partner for the characterization of genetically engineered cell lines, cell and gene therapy products and animal models for the global biopharmaceutical industry and leading research institutes worldwide. We develop and sell kits and services for targeted and complete sequencing of (trans)genes and gene editing events and provide services for the support in R&D in these fields.

Next to growing revenue from Cergentis’ current business, the company develops additional applications of its core technology. A recent development is the FFPE-TLC (Targeted Locus Capture) technology, with which we can detect all relevant mutations in FFPE tumor biopsy samples in one single test. With this, we strive to overcome limitations of conventional techniques such as FISH as well as to enable physicians to take smaller, minimal invasive biopsies.

It is our mission to improve the quality of genetic research: supporting biopharmaceutical R&D will accelerate the development of new treatments with better outcomes for patients all over the world.

Cergentis was founded in 2012 as a spin-off from Hubrecht Institute for Development Biology & Stem Cell Research and Royal Netherlands Academy of Arts and Sciences (KNAW).

© 2012-2022 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.
We use cookies for website analysis and marketing. By visiting and using our website you accept these cookies.